StocksMedium•15 October 2026•
1 min read
Takeda Launches ORZEYFUL for Narcolepsy in Japan and China
Key Facts
1Takeda announced the simultaneous launch of ORZEYFUL (oveporexton) in Japan and China for the treatment of narcolepsy type 1.
Takeda announced the simultaneous launch of ORZEYFUL (oveporexton) in Japan and China for the treatment of narcolepsy type 1. GuruFocus reported that the drug, a novel orexin receptor 2 agonist, is now available for clinicians to prescribe in these two major Asian markets.
The launch follows regulatory approvals and aims to address the underlying orexin deficiency associated with narcolepsy. The commercial rollout marks a positive milestone for the firm's healthcare franchise.